Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01067144 | Stanford Accelerated Recovery Trial (START) | terminated | Phase 3 | 422 | Stanford UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT02705404 | A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing | terminated | — | 8 | Mayo ClinicOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03054038 |
| Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer |
| terminated |
| Phase 1 |
| 22 |
| Vanderbilt-Ingram Cancer CenterOTHER |
| 1 |
| Apr 14, 2022 |
| clinicaltrials |
| NCT00286169 | Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC) | terminated | Phase 3 | 130 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT03754244 | A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics | terminated | Phase 1 | 1 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 7, 2022 | clinicaltrials |
| NCT02460367 | Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | terminated | Phase 1 | 16 | NewLink Genetics CorporationINDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02859415 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02932345 | Gefitinib Long-term Survivor Study | terminated | — | 59 | AstraZenecaINDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT02936947 | Study to Evaluate the Benefit of a High Frequency Ventilation System During Lung or Breast Cancer Radiotherapy Treatment | terminated | N/A | 8 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT00687986 | Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer(ROSEL) | terminated | Phase 3 | 22 | Amsterdam UMC, location VUmcOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer(ILIAD) | terminated | Phase 1 | 21 | MendusINDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | terminated | Phase 2 | 8 | TC BiopharmINDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT01455389 | TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer | terminated | Phase 1 / Phase 2 | 25 | Genprex, Inc.INDUSTRY | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02323126 | Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | terminated | Phase 2 | 64 | Novartis PharmaceuticalsINDUSTRY | 8 | Feb 28, 2022 | clinicaltrials |
| NCT04525391 | AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer(SUKSES-N5) | terminated | Phase 2 | 4 | Se-Hoon LeeOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT04958993 | A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 7 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT03988192 | Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy for Lung Cancer: Research on Biomarkers for Early Therapeutic Response(Immuno-VOC) | terminated | N/A | 60 | Hopital FochOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT03255083 | DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | terminated | Phase 1 | 13 | Daiichi SankyoINDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT02963610 | Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT00372073 | Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer | terminated | Phase 2 | 187 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 22, 2021 | clinicaltrials |
| NCT00885963 | A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer | terminated | Phase 2 | 62 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 22, 2021 | clinicaltrials |
| NCT03990077 | Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC | terminated | Phase 1 | 2 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | Dec 10, 2021 | clinicaltrials |
| NCT00960297 | Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC | terminated | Phase 2 | 4 | SCRI Development Innovations, LLCOTHER | 1 | Dec 6, 2021 | clinicaltrials |
| NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | terminated | Phase 1 / Phase 2 | 5 | Eli Lilly and CompanyINDUSTRY | 2 | Nov 24, 2021 | clinicaltrials |
| NCT04282694 | PRogetto Salute Parma(PSP) | terminated | — | 9 | University of ParmaOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT02934503 | Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) | terminated | Phase 2 | 5 | NYU Langone HealthOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03497026 | Auris Robotic Endoscopy System for Bronchoscopy | terminated | N/A | 4 | Auris Health, Inc.INDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03407040 | Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy | terminated | — | 98 | National Cancer Institute (NCI)NIH | 1 | Nov 10, 2021 | clinicaltrials |
| NCT00402883 | Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer | terminated | Phase 2 | 5 | SCRI Development Innovations, LLCOTHER | 1 | Nov 9, 2021 | clinicaltrials |
| NCT03998189 | Metabolic and Microbial Profiling of Lung Cancer | terminated | N/A | 1 | Wake Forest University Health SciencesOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT01741155 | Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) | terminated | Phase 2 | 34 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 13, 2021 | clinicaltrials |
| NCT01799135 | Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC) | terminated | N/A | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02387216 | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC(SHERLOC) | terminated | Phase 2 | 153 | Elevation OncologyINDUSTRY | 6 | Oct 12, 2021 | clinicaltrials |
| NCT03829618 | Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound | terminated | Phase 3 | 29 | Milton S. Hershey Medical CenterOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT01288430 | A Study of DS-2248 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 60 | Daiichi SankyoINDUSTRY | 1 | Oct 5, 2021 | clinicaltrials |
| NCT03624907 | Daily vs. Non-Daily SBRT for NSCLC | terminated | N/A | 20 | University of FloridaOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT03849950 | Self-Management and Activation to Reduce Treatment-Related Toxicities (SMARTCare) | terminated | N/A | 62 | University Health Network, TorontoOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT02111824 | A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy(MIMIG) | terminated | Phase 1 | 7 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT04140474 | Evaluation of the Archimedes ™ System for Transparenchymatous Access to Pulmonary Nodules.(SATAN) | terminated | N/A | 3 | University Hospital, LimogesOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | terminated | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT03387332 | APG-1252 in Patients With SCLC or Advanced Solid Tumors | terminated | Phase 1 | 24 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Aug 27, 2021 | clinicaltrials |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)(MERU) | terminated | Phase 3 | 748 | AbbVieINDUSTRY | 41 | Jul 29, 2021 | clinicaltrials |
| NCT03200600 | Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery | terminated | Phase 4 | 126 | Peking University First HospitalOTHER | 1 | Jul 13, 2021 | clinicaltrials |
| NCT01108666 | Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 7 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04289259 | Tumor Mutational Burden in Lung Cancer Patients(MUBULUC) | terminated | — | 6 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT02349633 | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | terminated | Phase 1 / Phase 2 | 65 | PfizerINDUSTRY | 4 | Jun 10, 2021 | clinicaltrials |
| NCT02475330 | Dietary Flaxseed in NSCLC | terminated | Phase 2 | 33 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 8, 2021 | clinicaltrials |
Data updated 23 days agoSource updated May 5, 2022source: clinicaltrials